WG1 Sample selection
Deliverable D1.2.
Report on the coordination of information seeking tracing, collection and data curation of the selected samples
WG1 Sample selection
Deliverable D1.1.
Report on the common understanding of the haplo selected CB samples selection procedure
Working Group 2
Deliverable D2.1
T2.1. Literature review on reprogramming methodologies for hiPSC generation from haplo selected cord blood samples
Working Group 2
Deliverable D2.2
Reprogramming of CD34+ cells extracted from haplotype matched cord blood units by transduction with CTS CytoTune iPS Sendai 2.1 Reprogramming Kit under GMP compliant conditions
Working Group 3
Deliverable D3.1
Quality control and qualification of hiPSC banks for clinical translation
Working Group 3
Deliverable D3.2
Report of database for inclusion into European human Pluripotent Stem Cell Registry (hPSCreg)
Working Group 4
Deliverable D4.1
Regulatory road map from donor samples to iPSC production for manufacture of cell therapy products
Working Group 4
Deliverable D4.2
Guidelines for promoting quality and safety of hPSC-based medicines and cell therapy products
Working Group 5
Deliverable D5.1
Report on the activity and management co-ordination and progress monitoring plan
Working Group 5
Deliverable D5.2
Ethical issues associated with the use of infant donors of biological material for establishing induced pluripotent stem cell banks
Working Group 5
Deliverable D5.3
Informed consent documents (General Information Document and Informed Consent Form) for adult and infant donors to HLA-haplotyped iPSC biobanks
Working Group 6
Deliverables 6.1
Deliverable D6.1 (M15): Training programme and mentoring for young researchers, and
trainee reports on training exchanges.
Working Group 6
Deliverables 6.2
Deliverable D6.2 (M12): Report of portal development and of the launching of the
website.
Working Group 6
Deliverable D6.3
Deliverable D6.3 (M48): Report of use of social media, presentations in meetings and collaborations with other initiatives
Working Group 7
Deliverable D7.1
Summary of safety, clinical and regulatory requirements for cell therapy with hiPSC-derivatives
Working Group 7
Deliverable D7.2
Summary of safety, clinical and regulatory requirements for cell therapy with hiPSC-derivatives (consolidated version)